samedan logo
 
 
 
spacer
home > ebr > spring 2003 > large-scale, comprehensive quality control and analysis of high-throughput screening data
PUBLICATIONS
European Biopharmaceutical Review

Large-Scale, Comprehensive Quality Control and Analysis of High-Throughput Screening Data

High-throughput screening (HTS) is used to search a vast area of the chemical universe for bioactive compounds and provides biological data on different targets from standardised, sensitive and well-controlled experiments for hundreds of thousands of compounds. However, this wealth of information is rarely exploited to its fullest extent and expensive resources are therefore often wasted.

In order to address this problem, intelligent methods and software to process and combine results from different HTS screens, secondary tests and lead profiling experiments are being developed. Data quality, biological side effects and chemical relationships are addressed at every stage, improving guidance for compound selection in screening and optimisation cycles. In support of the screening workflow, the analysis process consists of the following five steps: quality control, standardisation, compound classification, structure-activity relationship (SAR) analysis and pharmacological classification.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Colin J Hardy, Director of Inhalation Studies at Huntingdon Life Sciences

Swen Reimann has a degree in Engineering from the Polytechnicum Winterthur, Switzerland and Hoogeschool Limburg, The Netherlands, as well as a business degree from the University of California Berkeley Extension. He has worked for two leading US software companies in sales and marketing positions prior to joining Genedata in 2001, where he currently serves as a Marketing and Sales Manager for Screener, Genedata's software suite for the scientific analysis of high-throughput screening data.

Michael Lindemann obtained a PhD in Physics from the University of Kiel for his work on multivariate time series analysis applied to human motor control. Previous to this he obtained a MSc from Michigan State University. Dr Lindemann acted as a consultant and IT trainer for several companies prior to joining Genedata in 2001 where he currently serves as Product Manager for Screener.

Bernd Rinn obtained a PhD in Physics from the University of Konstanz for his work on transport and physical ageing in disordered systems. During his studies Dr Rinn gained experience in building and maintaining IT systems for scientific computing and business applications. He joined Genedata in 2001 where he helped in designing and building the Screener system. Currently he leads the development of Screener with a focus on software architecture and algorithms.

Olivier Lefèvre obtained a PhD in Physics from the University of Paris VI for work on neural network models. Prior to this he studied molecular biology and biophysics. For the last eight years he has been working as a software developer, first at NYU Medical School and then at UBS Warburg. He joined GeneData in 2001 where he designed and wrote the AssayAnalyzer module of Screener.

Stephan Heyse earned his PhD in Biophysics from the Swiss Federal Institute of Technology in 1997 for his investigation of functionally active G protein-coupled receptors embedded in supported lipid membranes. He gained practical experience in pharmaceutical high-throughput screening at Bayer AG (Germany), where he headed a screening laboratory. Dr Heyse manages the scientific and technical development of Screener.

spacer
Swen Reimann
spacer
spacer
spacer
Michael Lindemann
spacer
spacer
spacer
Bernd Rinn
spacer
spacer
spacer
Olivier Lefèvre
spacer
spacer
spacer
Stephan Heyse
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders

July 12, 2020 - The Data Demonstrating Benefits of Pharmacokinetic-Guided Prophylaxis Therapy in Hemophilia and von Willebrand Disease are Among 13 Presentations from Takeda’s Hematology Portfolio and Pipeline
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement